Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC‐MS / MS
Thoracic Cancer · 2023-11 · 14 (33) · 3331-3341
DOI: 10.1111/1759-7714.15125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 28.09.2023. Verfasst von Mengming Xia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ningbo Medical Center Lihuili Hospital, Ningbo, China. Hauptthemen laut MEDLINE: Azoles, Ketoconazole. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Key Research and Development Project of Lishui, Public Welfare Technology Research Funding Project of Zhejiang.
Abstract (Originalsprache)
Background
Lenvatinib is a multitargeted tyrosine kinase inhibitor used in the treatment of a variety of solid tumors. This study aims to investigate the potential pharmacokinetic interactions between lenvatinib and various azoles (ketoconazole, voriconazole, isavuconazole and posaconazole) when orally administered to rats.
Methods
A total of 30 Sprague–Dawley rats were randomly allocated into five groups and administered 20 mg/kg of ketoconazole, voriconazole, isavuconazole and 30 mg/kg of posaconazole and 0.5% CMC‐Na, through gavage for a duration of 7 days prior to the commencement of the experiment. On the final day, the rats were given 10 mg/kg of lenvatinib. The blood concentration of lenvatinib was determined using UPLC‐MS–MS. In vitro lenvatinib were incubated with azoles and rat liver microsomes (RLMs) or human liver microsomes (HLMs). Molecular docking was lastly used to examine the binding strength of the enzymes and ligands with Autodock Vina.
Results
AUC and C max of lenvatinib significantly increased with each of the azoles ( p < 0.05), whereas CLz/F decreased 0.83‐flod, 0.41‐fold ( p < 0.05) and 0.72‐fold ( p < 0.01) in voriconazole, isavuconazole and ketoconazole in rats. The IC50 of lenvatinib with the azoles were 0.237, 1.300, 0.355 and 2.403 μM in RLMs and 0.160, 1.933, 3.622 and 1.831 μM in HLMs. Molecular docking analysis suggested that azoles exhibited a strong binding ability towards the target enzymes.
Conclusion
It is imperative to acknowledge the potential drug–drug interactions mediated by CYP3A4 between azoles and lenvatinib, as these interactions hold significant implications for their clinical utilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Ningbo Medical Center Lihuili Hospital, Ningbo, China.
- Key Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui People's Hospital, Zhejiang, China.
- Department of Thoracic Surgery, Beijing Hospital, National Center of Gerontology, Beijing, China.
ORCID-Profile: Quan Zhou, Shuanghu Wang, Qingjun Wu, Aixia Han
Förderung
- Key Research and Development Project of Lishui
- Public Welfare Technology Research Funding Project of Zhejiang
Zitieren
APA
Xia, M., Song, X., Lu, Z., Wang, Y., Zhou, Q., Geng, P., Wang, S., Zhou, Y., Wu, Q., & Han, A. (2023). Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC‐MS / MS. Thoracic Cancer, 14(33), 3331-3341. https://doi.org/10.1111/1759-7714.15125
Vancouver
Xia M, Song X, Lu Z, Wang Y, Zhou Q, Geng P, et al. Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC‐MS / MS. Thoracic Cancer. 2023;14(33):3331-3341. doi:10.1111/1759-7714.15125
BibTeX
@article{Xia2023,
author = {Xia, Mengming and Song, Xueyi and Lu, Zebei and Wang, Yu and Zhou, Quan and Geng, Peiwu and Wang, Shuanghu and Zhou, Yunfang and Wu, Qingjun and Han, Aixia},
title = {Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC‐MS / MS},
journal = {Thoracic Cancer},
year = {2023},
volume = {14},
number = {33},
pages = {3331--3341},
doi = {10.1111/1759-7714.15125}
}
EUVIMED